Maravai LifeSciences Holdings Inc.: CEO buys shares for $1.5 million - Long-term perspective will be shaped by the expansion of mRNA applications
Reading Time: 1 minute
Maravai LifeSciences Holdings Inc. (MRVI) operates as a company in the life sciences sector, offering critical, high-quality products and services that enable the development of novel drug therapies, diagnostics, and vaccines. The report released on November 6 for the third quarter shows a significant decline in revenue, primarily due to the decrease in demand for COVID-19-related products. Total revenue for the third quarter of 2025 amounted to $41.6 million, representing a decrease of 39.7% compared to the same period last year and falling...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
